Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | THAR | Common Stock | Purchase | $10.1K | +5K | +86.84% | $2.02 | 10.8K | Nov 13, 2024 | Direct | |
holding | THAR | Common Stock | 2.59K | Nov 13, 2024 | See Footnote | F1 | |||||
holding | THAR | Common Stock | 21 | Nov 13, 2024 | See Footnote | F1 |
Id | Content |
---|---|
F1 | 2,593 shares of common stock are held indirectly by Highpoint Pharmaceuticals, LLC and 21 shares of common stock are held by Channel BioConsulting LLC. The Reporting Person is the managing member of each of Highpoint Pharmaceuticals, LLC and Channel BioConsulting LLC and in such capacity has the right to vote and dispose of the securities held by such entities. |